CJC-1295 and duration — Peptide Pros USA

Albumin binding

I admire CJC-1295 DAC’s albumin-binding design. Its linker attaches the peptide to serum albumin, a circulating protein, so the signal persists far longer. CJC-1295 also has four amino-acid substitutions that resist breakdown; the form commonly called no-DAC or Modified GRF 1-29 lacks the albumin-binding addition. The GHRH review explains the broader rationale for this kind of design.

The original albumin-bioconjugate experiment in rats found approximately a 4-fold increase in GH exposure over 2 hours compared with unmodified hGRF(1-29), and albumin-bound peptide remained detectable beyond 72 hours. That is a rat chemistry and pharmacology result. It helps explain why the later human work concentrated on duration.

Human GH and IGF-1 duration

In healthy adults aged 21 to 61, single subcutaneous CJC-1295 doses produced 2- to 10-fold increases in mean plasma GH for 6 days or more and 1.5- to 3-fold increases in IGF-1 for 9–11 days. Estimated half-life was 5.8–8.1 days; after multiple doses, IGF-1 remained above baseline for up to 28 days. These findings concern the long-acting DAC form.

That is a substantial pharmacological effect. I would still ask the duration to justify itself against a practical outcome: function, symptoms or another prespecified benefit. The study established hormone exposure in healthy adults. It left those larger questions open.

Pulses during sustained stimulation

The pulsatility study in healthy men aged 20 to 40 found that the frequency and magnitude of GH pulses persisted under sustained CJC-1295 stimulation. Basal GH rose approximately 7.5-fold, mean GH by about 46% and IGF-1 by about 45% one week later. Preserved pulses therefore coexisted with a changed background level.

The serum-protein study in 11 healthy young men adds a different kind of measurement: changes in the serum protein profile correlated with IGF-1, identifying candidate biomarkers of stimulation. I appreciate those as signs that the intervention reached beyond a single assay; they provide no direct answer about feeling or functioning better.

Identification by mass spectrometry

The analytical identification of CJC-1295 in a seized preparation used high-resolution mass spectrometry to establish what an unknown material contained. It is a useful companion to the DAC/no-DAC confusion: peptide identity requires more than a familiar name.

I distrust arguments that treat every item called CJC-1295 as interchangeable. A short-acting no-DAC preparation cannot simply inherit the long-acting DAC study’s duration. The formulation is a substantial part of the comparison.

Safety, development and approval

CJC-1295 has never been FDA-approved. FDA’s current record lists a withdrawn bulk-substance nomination while retaining immunogenicity concerns, meaning the possibility of an immune response to the peptide. A withdrawn nomination authorizes no compounding. The current clinical record remains early and limited, as the human pharmacology studies make clear.

The original DAC program was discontinued after a Phase 2 trial in HIV-associated visceral obesity. A death during that development era is cited in the history, but the public record did not establish a causal link to CJC-1295. It would be unfair to turn that uncertainty into a proven drug-caused death.

The secretagogue safety review describes the class concern over insulin sensitivity and blood glucose. Fluid retention and the theoretical cancer concern from sustained GH/IGF-1 stimulation also remain relevant. Community descriptions of deeper sleep, recovery, bloating, tingling and fatigue are anecdotal accounts, not clinical evidence. CJC-1295 is prohibited in sport under WADA S2. The comparison separates this duration record from sermorelin’s and ipamorelin’s.